Light-powered biodegradation of Imidacloprid by Scenedesmus sp. TXH202001: Assessing complete removal, metabolic pathways, and toxicity verification.

Imidacloprid (IMI) is used extensively as an insecticide and poses a significant risk to both the ecological environment and human health. Biological methods are currently gaining recognition among the different strategies tested for wastewater treatment. This study focused on evaluating a recently discovered green alga, Scenedesmus sp. TXH202001, isolated from a municipal wastewater treatment plant (WWTP), exhibited notable capacity for IMI removal. After an 18-day evaluation, medium IMI concentrations (50 and 100 mg/L) facilitated the growth of microalgae whereas low (5 and 20 mg/L) and high (150 mg/L) concentrations had no discernible impact. No statistically significant disparities were detected in Fv/Fm, Malonaldehyde or Superoxide dismutase across all concentrations, suggesting Scenedesmus sp. TXH202001 exhibited notable resilience and adaptability to IMI conditions. Most notably, Scenedesmus sp. TXH202001 successfully eliminated > 99 % of IMI within 18 days subjected to IMI concentrations as high as 150 mg/L, which was contingent on the environmental factor of illumination. Molecular docking was used to identify the chemical reaction sites between IMI and typical degrading enzyme CYP450. Furthermore, the study revealed that the primary path for IMI removal was biodegradation and verified that the toxicity of the degraded product was lower than parent IMI in Caenorhabditis elegans. The efficacy of Scenedesmus sp. TXH202001 in wastewater was exceptional, thereby validating its practical utility.

Human Hepatobiliary Organoids: Recent Advances in Drug Toxicity Verification and Drug Screening.

Many drug and therapeutic modalities have emerged over the past few years. However, successful commercialization is dependent on their safety and efficacy evaluations. Several preclinical models are available for drug-screening and safety evaluations, including cellular- and molecular-level models, tissue and organoid models, and animal models. Organoids are three-dimensional cell cultures derived from primary tissues or stem cells that are structurally and functionally similar to the original organs and can self-renew, and they are used to establish various disease models. Human hepatobiliary organoids have been used to study the pathogenesis of diseases, such as hepatitis, liver fibrosis, hepatocellular carcinoma, primary sclerosing cholangitis and biliary tract cancer, as they retain the physiological and histological characteristics of the liver and bile ducts. Here, we review recent research progress in validating drug toxicity, drug screening and personalized therapy for hepatobiliary-related diseases using human hepatobiliary organoid models, discuss the challenges encountered in current research and evaluate the possible solutions.